Physician profile
Ralph Yung
NPI 1356420111
$2,796.07
in general payments reported to CMS, 2019-2025
12 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,863 · 2020: $846 · 2021: $87.07.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $850.21 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $709.73 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $522.88 | 2019-2020 | |
| Zealand Pharma US, INC. | $212.87 | 2020 | |
| Allergan, INC. | $151.26 | 2019-2020 | |
| Amarin Pharma, INC. | $135.26 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $63.55 | 2019 | |
| Abbvie INC. | $51.85 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $44.64 | 2019-2021 | |
| Horizon Therapeutics Plc | $28.36 | 2019-2020 | |
| Scilex Pharmaceuticals INC. | $13.03 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $12.43 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ralph Yung listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.